ASXC

About Asensus Surgical, Inc.

Asensus Surgical, Inc., a medical technology enterprise established in 2006 and headquartered in Durham, North Carolina, focuses on the research, development, and commercialization of robotic medical devices. Its core mission is to elevate minimally invasive surgical procedures throughout the United States, Europe, and Asia through innovative robotic solutions. The company's unique approach involves digitally bridging the gap between surgeons and patients, thereby introducing a new paradigm of "Performance-Guided surgery." This system aims to equip surgeons with critical clinical intelligence, ensuring consistently superior patient outcomes and setting a higher benchmark for surgical standards. Key products include the Senhance Surgical system, a multi-port robotic platform that can maneuver up to four arms to precisely control surgical instruments and a camera during laparoscopic operations. Their product line also features a range of specialized instruments, such as 3mm diameter instruments, 3mm and 5mm hooks, and articulating tools. Additionally, they offer the Senhance ultrasonic system, an advanced energy device designed for accurate, controlled tissue ligation and division. The company, initially known as TransEnterix, Inc., officially rebranded to Asensus Surgical, Inc. in February 2021.

CEO: Anthony Fernando
IPO Date: Aug 6, 1991

Market Data

Open: $0.346
High: $0.3495
Low: $0.346
Volume: 3.9M
52W High: $0.3993
52W Low: $0.169

Valuation

Market Cap: $94.9M
Enterprise Value: $83.5M

Financials

Free Cash Flow: -$64.2M
Revenue: $8.6M
Net Income: -$78.4M
Cash: $17.1M
Debt: $5.7M

Events

EarningsAug 13

EPS est. -0.05 · actual -0.07